GALT cross above 200 day moving average after a lengthy period of consolidation in tightening trading range.
Cup and handle.
Leading drug in a pivotal clinical trial for advanced cirrhosis.
High insider ownership of shares
Recent hiring of a renowned liver expert VP from big pharma
Several insider buys from board of directors members in recent days.
CEO takes 80% pay in shares.
The multi-billionaire chairman added $40 million stake in past couple years.
Also, there is strong support at this price level.
GALT reported positive results for cancer immunotherapy one week ago. This was followed by algorithm trading taking the stock price lower. There is high open interest on $3, $4, and $5 calls expiring today. The price should reverse and move higher with the expiration of these calls, since the options traders accomplished what they were after to keep below the...
Bullish reversal indicators.
Increasing volume with solid support, as GALT enters 2021 catalysts.
NASDAQ:GALT
Due Diligence Cliff's Notes:
— Leading inhibitor under development for Galectin-3, key native immune system protein involved in numerous inflammatory and fibrotic diseases and various cancers.
— The only drug that has ever shown any clinically meaningful...
